Trial · NCT03334318
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | iGFR at the end of the PERL trial | Week 164 of the PERL trial | Glomerular filtration rate (GFR) at the end of the PERL trial, measured by the plasma clearance of non-radioactive iohexol (iGFR) and adjusted for the iGFR at baseline. |
| Secondary | HbA1c at week 80 of the PERL trial | Week 80 of the PERL Trial | Hba1c value at week 80 of the PERL trial |
| Secondary | HbA1c at week 96 of the PERL trial | Week 96 of the PERL Trial | Hba1c value at week 96 of the PERL trial |
| Secondary | HbA1c at week 112 of the PERL trial | Week 112 of the PERL Trial | Hba1c value at week 112 of the PERL trial |
| Secondary | HbA1c at week 128 of the PERL trial | Week 128 of the PERL Trial | Hba1c value at week 128 of the PERL trial |
| Secondary | HbA1c at week 142 of the PERL trial | Week 142 of the PERL Trial | Hba1c value at week 142 of the PERL trial |
| Secondary | HbA1c at week 156 of the PERL trial | Week 156 of the PERL Trial | Hba1c value at week 156 of the PERL trial |
| Secondary | HbA1c at week 164 of the PERL trial | Week 164 of the PERL Trial | Hba1c value at week 164 of the PERL trial |
| Secondary | Mean blood glucose | From week 80 to week 164 of the PERL trial | Mean of blood glucose values measured by continuous glucose monitoring |
| Secondary | CV (coefficient of variation) of blood glucose | From week 80 to week 164 of the PERL trial | Coefficient of variation of blood glucose values measured by continuous glucose monitoring |
| Secondary | % time 70-180 mg/dL | From week 80 to week 164 of the PERL trial | Percentage of time with blood glucose in the 70-180 mg/dL range (as measured by continuous glucose monitoring) |
| Secondary | % time below 54 mg/dL | From week 80 to week 164 of the PERL trial | Percentage of time with blood glucose below 54 mg/dL (as measured by continuous glucose monitoring) |
| Secondary | % time above 180 mg/dL | From week 80 to week 164 of the PERL trial | Percentage of time with blood glucose above 180 mg/dL (as measured by continuous glucose monitoring) |
| Secondary | % time above 250 mg/dL | From week 80 to week 164 of the PERL trial | Percentage of time with blood glucose above 250 mg/dL (as measured by continuous glucose monitoring) |
| Secondary | MAGE (Mean amplitude of glucose excursions) | From week 80 to week 164 of the PERL trial | Mean amplitude of glucose excursions as measured by continuous glucose monitoring |
| Secondary | LBGI (Low blood glucose index) | From week 80 to week 164 of the PERL trial | Low blood glucose index based on blood glucose values measured by continuous glucose monitoring |
| Secondary | HBGI (High blood glucose index) | From week 80 to week 164 of the PERL trial | High blood glucose index based on blood glucose values measured by continuous glucose monitoring |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03334318/registered